Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin vs Huachansu in Advanced HCC (BESTPOP)
NCT05594927Phase 3Recruiting
- Start
- Dec 2022
- Primary completion
- Aug 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Icaritin in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Overall Survival at 24 months. Started Dec 2022; status: recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05594927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594927.